Loading...
WS16.1 Clinical Outcomes of Real-World Kalydeco (CORK) study – Investigating the impact of CFTR potentiation on the intestinal microbiota, exocrine pancreatic function and intestinal inflammation prospectively over 12 months
Deane, Jennifer Ronan, N. J. O'Callaghan, G. P. Fouhy, Fiona Rea, Mary O'Sullivan, Orla Hill, C. J. Shanahan, F. Ross, R Paul McCarthy, M.
Deane, Jennifer
Ronan, N. J.
O'Callaghan, G. P.
Fouhy, Fiona
Rea, Mary
O'Sullivan, Orla
Hill, C. J.
Shanahan, F.
Ross, R Paul
McCarthy, M.
Citations
Altmetric:
Keywords
Date
2015-06-05
Collections
Files
Loading...
main article
Adobe PDF, 61.15 KB
Research Projects
Organizational Units
Journal Issue
Citation
Deane, J., Ronan, N., O'Callaghan, G., Fouhy, F., Rea, M., O'Sullivan, O., Hill, C., Shanahan, F., Ross, R., McCarthy, M., Murphy, D., Eustace, J., Stanton, C. and Plant, B. (2015). WS16.1 Clinical Outcomes of Real-World Kalydeco (CORK) study – Investigating the impact of CFTR potentiation on the intestinal microbiota, exocrine pancreatic function and intestinal inflammation prospectively over 12 months. Journal of Cystic Fibrosis, 14, Suppl. 1, S29. doi: https://dx.doi.org/10.1016/s1569-1993(15)30090-4.
Abstract
Objectives
Ivacaftor is effective in the treatment of patients with CF and the G551D gating mutation. We present faecal analysis results of the CORK cohort, a single-centre, adult (n = 20), prospective, longitudinal study of G551D clinical responders (median follow-up 12 months), examining the gut microbiota, exocrine pancreatic function and intestinal inflammation on a 3 monthly basis after commencing treatment.